title: [Round robin test for detection of genomic aberrations in non-Hodgkin lymphoma by in situ hybridization].
abstract: BACKGROUND
  The detection of characteristic genomic aberrations by fluorescence in situ hybridization (FISH) has a high diagnostic impact on lymphomas according to the World Health Organization (WHO). To investigate the reproducibility of non-isotopic ISH results a multicenter trial was carried out involving eight institutes for hematopathology.
  
  
  METHODS
  Analyses were performed on two diffuse large B-cell lymphomas (DLBCL) without known aberrations, on one follicular lymphoma with a IGH/BCL2 translocation and BCL6 split and on two B-cell lymphomas intermediate between DLBCL and Burkitt's lymphoma with c-MYC and BCL2 rearrangements, one with an additional BCL6 split. Break-apart probes for BCL6 and c-MYC, as well as fusion probes for the c-MYC/IGH and the IGH/BCL2 translocations were used.
  
  
  RESULTS
  All aberrations were correctly detected by all centres and no false positive or false negative results were obtained. The numbers of positive cells varied from 25% to 94%. Pearson's correlation coefficient between the centres was always > 0.8.
  
  
  CONCLUSIONS
  The ISH analysis of recurrent genomic aberrations in formalin-fixed paraffin-embedded (FFPE) tissue is a highly reproducible technique which yields substantial additive help for lymphoma diagnostics.
authors.affiliation: Institut für Pathologie, Universitätsklinikum Ulm, Albert-Einstein-Allee 23, Ulm, Germany. thomas.barth@uniklinik-ulm.de
authors.forename: T F E
authors.initials: TF
authors.lastname: Barth
authors.forename: L
authors.initials: L
authors.lastname: Floßbach
authors.forename: H-W
authors.initials: HW
authors.lastname: Bernd
authors.forename: R
authors.initials: R
authors.lastname: Bob
authors.forename: M
authors.initials: M
authors.lastname: Buck
authors.forename: S B
authors.initials: SB
authors.lastname: Cogliatti
authors.forename: A C
authors.initials: AC
authors.lastname: Feller
authors.forename: M L
authors.initials: ML
authors.lastname: Hansmann
authors.forename: S
authors.initials: S
authors.lastname: Hartmann
authors.forename: H
authors.initials: H
authors.lastname: Horn
authors.forename: W
authors.initials: W
authors.lastname: Klapper
authors.forename: D
authors.initials: D
authors.lastname: Kradolfer
authors.forename: T
authors.initials: T
authors.lastname: Mattfeldt
authors.forename: P
authors.initials: P
authors.lastname: Möller
authors.forename: A
authors.initials: A
authors.lastname: Rosenwald
authors.forename: H
authors.initials: H
authors.lastname: Stein
authors.forename: C
authors.initials: C
authors.lastname: Thorns
authors.forename: G
authors.initials: G
authors.lastname: Ott
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics; D002051:Burkitt Lymphoma / Q000175:diagnosis / Q000235:genetics / Q000473:pathology; D002869:Chromosome Aberrations; D004268:DNA-Binding Proteins / Q000235:genetics; D003937:Diagnosis, Differential; D016259:Genes, myc / Q000235:genetics; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000235:genetics; D017403:In Situ Hybridization / Q000379:methods*; D017404:In Situ Hybridization, Fluorescence / Q000379:methods; D008224:Lymphoma, Follicular / Q000175:diagnosis / Q000235:genetics / Q000473:pathology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000235:genetics / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000235:genetics* / Q000473:pathology; D051560:Proto-Oncogene Proteins c-bcl-6; D011785:Quality Assurance, Health Care; D015203:Reproducibility of Results; D014178:Translocation, Genetic / Q000235:genetics
chemical_list: C084103:BCL6 protein, human; D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; D007143:Immunoglobulin Heavy Chains; D051560:Proto-Oncogene Proteins c-bcl-6